home / stock / aldr / aldr news

ALDR News and Press, Alder BioPharmaceuticals Inc. From 02/25/19

Stock Information
Company Name: Alder BioPharmaceuticals Inc.
Stock Symbol: ALDR
Market: NASDAQ
Website: alderbio.com
Menu
ALDR ALDR Quote ALDR Short ALDR News ALDR Articles ALDR Message Board
Get ALDR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALDR - Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

- Completes eptinezumab’s Biologics License Application (BLA) submission - - Remains on track for eptinezumab’s commercial launch in Q1-2020 - - Strengthens leadership team with the appointments of Carlos Campoy as Chief Financial Officer and Dr. Paul Streck as C...
ALDR - Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

BOTHELL, Wash., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced it has submitted a Biologics License Application (BLA) to the U.S. F...

ALDR - Alder BioPharmaceuticals® to Present at the 8th Annual SVB Leerink Global Healthcare Conference

BOTHELL, Wash., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer...

ALDR - Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial and Operating Results

BOTHELL, Wash., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2018 financial a...
ALDR - Teva: Reasons To Avoid It In Favor Of Innovative Biotechs

Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...

ALDR - Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America - Fundamental Analysis, Key Performance Indications

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Varonis Systems, Inc. (NASDAQ:VRNS), Dolby Laboratories (NYSE:DLB), Alder...

ALDR - Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors ...
Previous 10 Next 10